NO131175B - - Google Patents
Download PDFInfo
- Publication number
- NO131175B NO131175B NO1181/69A NO118169A NO131175B NO 131175 B NO131175 B NO 131175B NO 1181/69 A NO1181/69 A NO 1181/69A NO 118169 A NO118169 A NO 118169A NO 131175 B NO131175 B NO 131175B
- Authority
- NO
- Norway
- Prior art keywords
- spirox
- methylene
- compounds
- ether
- approx
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- DKWOHBPRFZIUQL-UHFFFAOYSA-N dimethyl-methylidene-oxo-$l^{6}-sulfane Chemical compound C[S+](C)([CH2-])=O DKWOHBPRFZIUQL-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 9
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 9
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 7
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 7
- 229960002478 aldosterone Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- -1 20-spiroxa-4 Chemical compound 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05G—SAFES OR STRONG-ROOMS FOR VALUABLES; BANK PROTECTION DEVICES; SAFETY TRANSACTION PARTITIONS
- E05G1/00—Safes or strong-rooms for valuables
- E05G1/02—Details
- E05G1/024—Wall or panel structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71516068A | 1968-03-22 | 1968-03-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO131175B true NO131175B (da) | 1975-01-06 |
| NO131175C NO131175C (da) | 1975-04-16 |
Family
ID=24872890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1181/69A NO131175C (da) | 1968-03-22 | 1969-03-21 |
Country Status (14)
| Country | Link |
|---|---|
| AT (1) | AT297948B (da) |
| BE (1) | BE730163A (da) |
| BR (1) | BR6907426D0 (da) |
| CH (1) | CH525876A (da) |
| DK (1) | DK123353B (da) |
| FI (1) | FI47354C (da) |
| FR (1) | FR2004562A1 (da) |
| GB (1) | GB1235768A (da) |
| IE (1) | IE33205B1 (da) |
| IL (1) | IL31769A (da) |
| NL (1) | NL166267C (da) |
| NO (1) | NO131175C (da) |
| SE (1) | SE351636B (da) |
| YU (1) | YU34303B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792624A (fr) * | 1972-05-22 | 1973-06-12 | Merck & Co Inc | Composes inhibiteurs de l'aldosterone et leur obtention |
| DE2652761C2 (de) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| AT351191B (de) * | 1976-12-20 | 1979-07-10 | Hoffmann La Roche | Verfahren zur herstellung von neuen d-homo- steroiden |
| DE3222265A1 (de) * | 1982-06-09 | 1983-12-15 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6ss.7ss-methylen-17(alpha)-pregn-4-en-21.17-carbolactone, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| JPS59139400A (ja) * | 1983-01-31 | 1984-08-10 | Shionogi & Co Ltd | 抗アルドステロン活性ステロイド誘導体 |
-
1969
- 1969-03-04 NL NL6903322.A patent/NL166267C/xx not_active IP Right Cessation
- 1969-03-10 IL IL31769A patent/IL31769A/xx unknown
- 1969-03-10 YU YU581/69A patent/YU34303B/xx unknown
- 1969-03-11 IE IE317/69A patent/IE33205B1/xx unknown
- 1969-03-11 FI FI690718A patent/FI47354C/fi active
- 1969-03-13 SE SE03497/69A patent/SE351636B/xx unknown
- 1969-03-17 GB GB03874/69A patent/GB1235768A/en not_active Expired
- 1969-03-20 CH CH421969A patent/CH525876A/de not_active IP Right Cessation
- 1969-03-20 BE BE730163D patent/BE730163A/xx unknown
- 1969-03-20 AT AT277969A patent/AT297948B/de not_active IP Right Cessation
- 1969-03-21 NO NO1181/69A patent/NO131175C/no unknown
- 1969-03-21 DK DK157269AA patent/DK123353B/da unknown
- 1969-03-21 BR BR207426/69A patent/BR6907426D0/pt unknown
- 1969-03-21 FR FR6908468A patent/FR2004562A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IE33205B1 (en) | 1974-04-17 |
| NO131175C (da) | 1975-04-16 |
| YU58169A (en) | 1978-10-31 |
| IL31769A (en) | 1973-08-29 |
| DK123353B (da) | 1972-06-12 |
| CH525876A (de) | 1972-07-31 |
| FR2004562A1 (da) | 1969-11-28 |
| FI47354B (da) | 1973-07-31 |
| NL166267C (nl) | 1981-07-15 |
| DE1914507A1 (de) | 1969-10-09 |
| BR6907426D0 (pt) | 1973-05-31 |
| AT297948B (de) | 1972-04-10 |
| BE730163A (da) | 1969-09-22 |
| NL6903322A (da) | 1969-09-24 |
| SE351636B (da) | 1972-12-04 |
| YU34303B (en) | 1979-04-30 |
| IL31769A0 (en) | 1969-05-28 |
| IE33205L (en) | 1969-09-22 |
| NL166267B (nl) | 1981-02-16 |
| FI47354C (fi) | 1973-11-12 |
| GB1235768A (en) | 1971-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH668599A5 (de) | Substituierte androsta-1,4-dien-3,17-dione und verfahren zu deren herstellung. | |
| NO131175B (da) | ||
| US4917827A (en) | Process for the preparation of 9(11)-dehydro steroids | |
| NO128608B (da) | ||
| NO118975B (da) | ||
| US4456601A (en) | 3-Chloro-pregnane derivatives and a process for the preparation thereof | |
| EP0193871B1 (en) | 2-oxa- or aza-pregnane compounds | |
| DK167574B1 (da) | Fremgangsmaade til fremstilling af en 16,17-acetalsubstitueret androstan-17beta-(2-oxoethylenoxy)-forbindelse | |
| US4331663A (en) | 4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof | |
| US4192802A (en) | Process for the manufacture of steroid carboxylic acid lactones | |
| Nagarajan et al. | Nitroimidazoles: Part XX. Reactions of 2, 4-dinitroimidazole with 2-haloethanols, 3-chloropropionitrile & propylene oxide | |
| Dick et al. | Facile synthesis of 1, 2-trans-O-acetyl glycosyl chloride derivatives of cellobiose, lactose, and D-glucose | |
| SU576956A3 (ru) | Способ получени производных 3(3 оксо-17 -окси-6,7-метиленандростен-4-ил-17 )-пропионовой кислоты | |
| Sircar et al. | Free-radical bromination of methyl abietate by N-bromosuccinimide and solvolysis of the products | |
| DE2938313C2 (da) | ||
| Cook et al. | The conformational analysis of saturated heterocycles. Part XVII. Sulphonium salt formation by thiacyclohexanes | |
| EP1339733B1 (de) | Verfahren zur herstellung von 4-(17alpha-methyl-substituierten)3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1e oder 1z)-oximen | |
| EP0036218A2 (en) | Salts of the 3-hydroxy quinuclidine esters of a phenoxycarboxylic acid, a process for the preparation thereof, and related pharmaceutical compositions | |
| WO2009000834A1 (en) | Method for the purification of mycophenolate mofetil | |
| US2990415A (en) | 9-substituted delta4-androstenes | |
| DE1445184A1 (de) | Verfahren zur Herstellung von zentral erregend wirkenden Verbindungen | |
| DE1921462C3 (de) | Steroid oxazoline, Verfahren zu deren Herstellung und dieselben ent haltende Arzneimittel | |
| DE1914507C (de) | 6 alpha, 7 alpha bzw 6 beta, 7 beta Methylen 20 spirox 4 en 3 on Verbindungen und Verfahren zu deren Her stellung | |
| US3002984A (en) | Process for the preparation of 11-hydroxy-steroids | |
| EP0151094A2 (en) | Pharmacologically active imidazopyridine compounds |